What is Leerink Partnrs' Estimate for Quanterix Q2 Earnings?

Key Points

• Leerink Partners has lowered its Q2 2026 earnings estimate for Quanterix to ($0.20) per share, down from a previous estimate of ($0.17).
• Quanterix stock has a current market capitalization of $268.57 million and a consensus rating of "Hold" among analysts, with a target price of $11.75.
• Recent earnings results showed Quanterix missed expectations, reporting (0.47) EPS against the consensus estimate of (0.41) EPS.

Quanterix Corporation (NASDAQ:QTRX - Free Report) - Research analysts at Leerink Partnrs decreased their Q2 2026 earnings estimates for shares of Quanterix in a research report issued on Monday, October 13th. Leerink Partnrs analyst P. Souda now anticipates that the company will post earnings of ($0.20) per share for the quarter, down from their previous forecast of ($0.17). The consensus estimate for Quanterix's current full-year earnings is ($0.98) per share. Leerink Partnrs also issued estimates for Quanterix's Q3 2026 earnings at ($0.18) EPS, Q4 2026 earnings at ($0.10) EPS, FY2026 earnings at ($0.67) EPS and FY2027 earnings at ($0.43) EPS.

Several other equities analysts have also recently commented on QTRX. Weiss Ratings restated a "sell (d-)" rating on shares of Quanterix in a report on Wednesday, October 8th. Canaccord Genuity Group restated a "hold" rating and set a $5.00 price target (down from $12.00) on shares of Quanterix in a report on Monday, August 11th. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $11.75.

Quanterix Stock Down 1.4%

Quanterix stock opened at $5.78 on Thursday. The company's fifty day simple moving average is $5.08 and its 200-day simple moving average is $5.48. Quanterix has a 12 month low of $4.05 and a 12 month high of $15.67. The stock has a market cap of $268.57 million, a P/E ratio of -3.18 and a beta of 1.07.

Quanterix (NASDAQ:QTRX - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.06). Quanterix had a negative net margin of 56.04% and a negative return on equity of 18.41%. The firm had revenue of $24.48 million for the quarter, compared to analyst estimates of $29.73 million. Quanterix has set its FY 2025 guidance at EPS.

Institutional Investors Weigh In On Quanterix

A number of hedge funds have recently bought and sold shares of QTRX. Valmark Advisers Inc. boosted its holdings in Quanterix by 16.1% during the first quarter. Valmark Advisers Inc. now owns 244,854 shares of the company's stock valued at $1,594,000 after acquiring an additional 33,976 shares during the period. Allspring Global Investments Holdings LLC acquired a new position in shares of Quanterix during the first quarter valued at about $98,000. Aaron Wealth Advisors LLC acquired a new position in shares of Quanterix during the first quarter valued at about $79,000. Envestnet Asset Management Inc. raised its position in shares of Quanterix by 46.2% during the first quarter. Envestnet Asset Management Inc. now owns 500,398 shares of the company's stock valued at $3,258,000 after buying an additional 158,134 shares during the last quarter. Finally, Trium Capital LLP acquired a new position in shares of Quanterix during the first quarter valued at about $3,642,000. 86.48% of the stock is currently owned by institutional investors.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.